Directorate Change
June 25 2009 - 4:30AM
UK Regulatory
TIDMYRK
RNS Number : 4850U
York Pharma plc
25 June 2009
25 June 2009
York Pharma plc
("York" or the "Company")
Directorate change
York today announces that it has mutually agreed terms for the departure of
Terry Sadler, Founder and President from the Board.
The Company announced yesterday that discussions with Uluru Inc on the proposed
terms indicated in the announcement of 7 April 2009 had been terminated and the
requirement for the Company to repay to Uluru the $1 million line of credit
previously advanced by Uluru to York. Mr Sadler will resign from the Board of
Directors and leave the Company upon the repayment of the line of credit by
York.
As announced, York is now actively pursuing alternative funding facilities in
order to repay the line of credit before 22 July 2009 and to meet its ongoing
working capital requirements.
Commenting on Mr Sadler's departure, Max Dyer-Bartlett, Chairman of the Company
said "Terry achieved a tremendous amount in building the York business. He will
leave the Board with our thanks for the effort he has put in for the past six
years and for the support he has provided to the new team since their
appointment in January this year".
For more information please contact:
+---------------------------------------+----------------------------+
| York Pharma plc | Tel: +44 (0) 1908 764020 |
| Richard Anderson, Chief Executive | |
| Officer | |
| Ian Miscampbell, Chief Financial | |
| Officer | |
+---------------------------------------+----------------------------+
| Collins Stewart Europe Limited | Tel: +44 (0) 207 523 8350 |
| Hugh Field / Adam Cowen | |
+---------------------------------------+----------------------------+
| Financial Dynamics | Tel: +44 (0) 207 831 3113 |
| Ben Brewerton / Emma Thompson | |
+---------------------------------------+----------------------------+
Collins Stewart Europe Limited, which is authorised and regulated in the United
Kingdom by the Financial Services Authority, is acting as Nominated Advisor and
broker to York Pharma plc and will not be responsible to anyone other than York
Pharma plc for providing the protections afforded to clients of Collins Stewart
Europe Limited nor for providing advice in connection with any other matter
referred to herein.
=-o--
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASEUSWISUSEDM
York Pharma (LSE:YRK)
Historical Stock Chart
From Jun 2024 to Jul 2024
York Pharma (LSE:YRK)
Historical Stock Chart
From Jul 2023 to Jul 2024